ArticleInfectious diseases and therapy2023

Safety, Pharmacokinetics, Serum Neutralizing Titers, and Immunogenicity of Adintrevimab, a Monoclonal Antibody Targeting SARS-CoV-2: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Dose-escalation Study in Healthy Adults.

Pete Schmidt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.